Vaccines against Chlamydia trachomatis: Immunogenicity analysis via peptide pool
January 21, 2025
Dr. Lilian Schoefer
Research updates
Research updates
Scientists have investigated two novel recombinant vaccines based on the modified vaccinia virus Ankara (MVA). These vaccines express a chimeric protein containing several antigens from the most common serovars of Chlamydia trachomatis.
To analyze the immune responses elicited by these vaccines, the researchers developed the peptide pool spCTH522, which encompasses the entire chimeric protein. peptides&elephants synthesized the consecutive 15-mer peptides, which overlapped by 11 amino acids. In addition to its capacity to generate individual peptide pools, peptides&elephants has a large peptide shop from which the scientists selected more peptides.
To analyze the immune responses elicited by these vaccines, the researchers developed the peptide pool spCTH522, which encompasses the entire chimeric protein. peptides&elephants synthesized the consecutive 15-mer peptides, which overlapped by 11 amino acids. In addition to its capacity to generate individual peptide pools, peptides&elephants has a large peptide shop from which the scientists selected more peptides.
Chlamydia trachomatis: most common cause of STDs
Chlamydia trachomatis is the leading pathogen responsible for sexually transmitted diseases (STDs), with infection rates continuing to rise. Despite often being asymptomatic, chlamydia infection can have severe consequences, including sterility, if left untreated. Furthermore, Chlamydia trachomatis is associated with an increased risk of co-infection with other pathogens such as the human immunodeficiency virus (HIV). Unfortunately, a commercial vaccine against this pathogen is currently not available.
Novel vaccines based on the modified vaccinia virus Ankara
Giuseppe Andreacchio and colleagues from the Institute of Virology at the University Hospital Düsseldorf in Germany have now investigated two novel recombinant vaccines based on the modified vaccinia virus Ankara. [1] These vaccines express the proteins spCTH522 and CTH522:B7, which are designed to elicit an immune response against Chlamydia trachomatis. The chimeric protein CTH522 is composed of antigenic regions from the most common serovars of Chlamydia trachomatis:
- Amino acid sequence 56–349 of the major outer membrane protein (MOMP) of serovar D
- Amino acid sequence 282–349 of the external VD4 domain of serovar E
- Amino acid sequence 283–351 of the external VD4 domain of serovar F
- Amino acid sequence 283–351 of the external VD4 domain of serovar G
Immune response depends on mouse model
The researchers observed a significant difference in the immune responses between two mouse models: C57BL/6J mice and an HLA-transgenic mouse model.
In C57BL/6J mice, both vaccines elicited CD4+ T cell responses, but antigen-specific systemic CD8+ T cells were not detected. Notably, the membrane-anchored CTH522:B7 vaccine induced robust IgG2b and IgG2c antibody reactions. In an HLA-transgenic mouse model, however, the two recombinant vaccines induced Th1-directed CD4+ T cells and multifunctional CD8+ T cells. Once again, only the membrane-anchored vaccine CTH522:B7 generated antibody reactions.
To validate their results, the scientists used ovalbumin-specific peptides (OVA 257–264 and OVA 323–339) and peptides specific for the modified vaccinia virus Ankara (B8 20−27 and B5 46–60) as negative and positive controls, respectively.
Transgenic mouse model for HLA-restricted T cell responses
Since the researchers wanted to focus on the development of a vaccine that specifically targets CD8+ T cell responses, they turned their attention to the HLA-transgenic mouse model. The A2.DR1 mice used are knock-out mice for the major histocompatibility complexes (MHCs) I and II and transgenic for HLA-A*02:01/Db and HLA-DR1 as the sole sources of MHC-I and MHC-II. This genetic background allows the scientists to study T cell responses in a HLA-restricted manner.
The researchers immunized the HLA-transgenic mice intraperitoneally with either the modified wild-type vaccinia virus Ankara or the antigen-expressing variants spCTH522 (MVA-spCTH522) or CTH522:B7 (MVA-CTH522:B7). After 7 days, they removed the animals' spleens to examine the splenocytes.
Analysis of immune response using peptide pools and specific peptides
The scientists crushed the spleen on a 70 µm cell strainer to release the cells, then incubated them with lysis buffer for one minute at room temperature to remove the erythrocytes. They then passed the cells through another 70 µm cell strainer and counted them using a Neubauer cell counting chamber. They pipetted 200 µL of 2 × 106 cells into each well of a 96-well plate and incubated them for 4–5 hours with various peptide preparations:
- the entire spCTH522 peptide pool
- subsets of the spCTH522 peptide pool
- the specific peptides MOMP282–290 and MOMP200–209 or
- control peptides
All peptide preparations were added at a concentration of 5 µg/mL in the presence of 1 µg/mL brefeldin A.
Two HLA-A*02:01-restricted epitopes within the CTH522 protein sequence
Neither MVA-spCTH522 nor MVA-CTH522:B7 induced strong CD4+ T cell responses that were specific for the spCTH522 peptide pool (Figure). However, using the peptide pool, the researchers were able to identify two HLA-A*02:01-restricted epitopes within the CTH522 protein sequence that trigger CD8+ T cell responses (Figure). One epitope was the 9-mer NMFTPYIGV, which corresponds to MOMP282–290 and has previously been described as a dominant CD8+ T cell-specific epitope in PBMCs of Chlamydia trachomatis-positive patients. [2] The other epitope was new: the 10-mer ALWECGCATL, which corresponds to MOMP200–209.
When the HLA-transgenic mice received a booster dose of MVA-spCTH522 or MVA-CTH522:B7 after 28 days, this increased the magnitude of the T cell responses.
New epitope and insights for improved vaccine development
With MOMP200–209, the scientists were able to identify a new HLA-A*02:01-restricted epitope within the CTH522 protein sequence. Their results also contribute to understanding how vaccine development can be improved for targeted immune responses. Their studies show the importance of both antigen localization and the selection of suitable animal models to study the immune response of Chlamydia trachomatis vaccine candidates. Whether the immune responses observed in the mouse models correlate with those required for protection against chlamydia in humans remains to be determined.
Literature:
- Andreacchio, Giuseppe et al. “Viral Vector-Based Chlamydia trachomatis Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.” Vaccines vol. 12,8 944. 22 Aug. 2024, doi:10.3390/vaccines12080944
- Kim, S K et al. “Induction of HLA class I-restricted CD8+ CTLs specific for the major outer membrane protein of Chlamydia trachomatis in human genital tract infections.” Journal of immunology (Baltimore, Md. : 1950) vol. 162,11 (1999): 6855-66.
Skip product gallery
Related products
Tip
Actin Peptide Pool, human
€237.50*
The HUMAN (Actin) Peptide Pool consists of 92 overlapping peptides derived from a peptide scan through Actin, alpha skeletal muscle (UniProt ID: P68133) of Homo sapiens. The peptides are 15mers that overlap by 11 amino acids.
One unit of HUMAN (Actin) Peptide Pool allows the stimulation of 2,5 x 108 cells.
Actin is a ubiquitously expressed protein and therefore an excellent negative control for T cell assays. Relevant controls are critical for measuring antigen-specific responses as they allow accurate interpretation of test results. The HUMAN (Actin) Peptide Pool can rule out non-specific binding of peptides to the tested T cells, while a negative control with medium detects general background signals.
Examples of publications where actin was used as a negative control:
Baker FL, et al.: Exercise mobilizes diverse antigen specific T-cells and elevates neutralizing antibodies in humans with natural immunity to SARS CoV-2. Brain Behav Immun Health. 2023 Mar;28:100600. doi: 10.1016/j.bbih.2023.100600.
Sweeney, E et al.: Photothermal Prussian blue nanoparticles generate potent multi‐targeted tumor‐specific T cells as an adoptive cell therapy. Bioeng Transl Med. 2023;e10639. doi.org/10.1002/btm2.10639.
Roy, P et al.: Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B. Circ Res. 2022 Jul 22;131(3):258-276. doi: 10.1161/CIRCRESAHA.122.321116.
Lasagna, Angioletta et al. “The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.”Human vaccines & immunotherapeutics vol. 19,3 (2023): 2288282. doi:10.1080/21645515.2023.2288282
B8R 20-27 (H-2 Kb)
€105.00*
The linear peptide B8R 20-27, with the amino acid sequence TSYKFESV (epitope ID 66504), is a well-established H2-Kb-restricted epitope conserved among various Vaccinia virus strains. [1] It is part of the:
Soluble interferon gamma receptor OPG193 (UniProt:P24770) from Vaccinia virus
IFN-gamma receptor (UniProt:Q66793) from Ectromelia mousepox virus
IFN-gamma receptor-like protein (UniProt:G0XTP5) from Cowpox virus
The Vaccinia virus was the live vaccine used to eradicate smallpox. It belongs to the orthopoxvirus family and provides protection against a range of orthopoxviruses. Currently, the most concerning of these is the monkeypox virus, but human cowpox infections are also being reported regularly in Europe. [1]
The B8R 20-27 peptide, TSYKFESV, is also contained in recombinant and non-recombinant Modified Vaccinia virus Ankara (MVA). [1] The Modified Vaccinia virus Ankara has greatly reduced virulence and can no longer replicate in most mammalian cells. [2] It is often used as a vaccine vector, due to its cost-effectiveness, safety, and high immunogenicity. Recombinant MVA vaccines can generate robust humoral and cellular immune responses against various pathogens.
In vaccine development, the B8R 20-27 peptide is used as a positive control to demonstrate that a lack of response is not due to immunization failure. The vaccinia virus B8R gene encodes a homolog of the secreted IFN-γ receptor. By binding to IFN-γ, B8R neutralizes its antiviral activity and is therefore involved in virus evasion of host interferon responses. [1,3]You can read a current application example in our blog post "Vaccines against Chlamydia trachomatis: Immunogenicity analysis via peptide pool" or view the original publication [4] via the link under the References tab.
CEF (classic) Peptide Pool (>95% HPLC)
€126.30*
The CEF peptide pool is a lyophilized mixture of 23 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells.
The peptides of this product are supplied as trifluoracetate salts.
One unit allows the stimulation of 2,5 x 108 cells.
CEF control Peptide Pool (>95% HPLC, advanced)
€151.30*
The CEF peptide pool is a lyophilized mixture of 32 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus. It consists of defined HLA class I-restricted T cell epitopes from these three viruses, and can be used as a positive control to stimulate T cells. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells.
One unit allows the stimulation of 2,5 x 108 cells.These are sequence, source and corresponding MHC class I molecule of each peptide:
Sequence
Source
MHC class I molecule
H-VSDGGPNLY-OH
Influenza A
HLA-A1
H-CTELKLSDY-OH
Influenza A
HLA-A1
H-GILGFVFTL-OH
Influenza M
HLA-A2
H-FMYSDFHFI-OH
Influenza A
HLA-A2
H-CLGGLLTMV-OH
EBV LMP2A
HLA-A2
H-GLCTLVAML-OH
EBV BMLF1
HLA-A2
H-NLVPMVATV-OH
HCMV pp65
HLA-A2
H-KTGGPIYKR-OH
Influenza NP
HLA-A68
H-RVLSFIKGTK-OH
Influenza NP
HLA-A3
H-ILRGSVAHK-OH
Influenza A
HLA-A3
H-RVRAYTYSK-OH
EBV
HLA-A3
H-RLRAEAQVK-OH
EBV
HLA-A3
H-SIIPSGPLK-OH
Influenza M
HLA-A3/A11/A6
H-AVFDRKSDAK-OH
EBV EBNA 4NP
HLA-A11
H-IVTDFSVIK-OH
EBV
HLA-A11
H-ATIGTAMYK-OH
EBV
HLA-A11
H-DYCNVLNKEF-OH
EBV RTA
HLA-A24
H-LPFDKTTVM-OH
Influenza NP
HLA-B7
H-RPPIFIRRL-OH
EBV
HLA-B7
H-ELRSRYWAI-OH
Influenza NP
HLA-B8
H-RAKFKQLL-OH
EBV B2LF-1
HLA-B8
H-FLRGRAYGL-OH
EBV EBNA 3A
HLA-B8
H-QAKWRLQTL-OH
EBV EBNA 3
HLA-B8
H-SDEEEAIVAYTL-OH
HCMV
HLA-B18
H-SRYWAIRTR-OH
Influenza NP
HLA-B27
H-ASCMGLIY-OH
Influenza A
HLA-B27
H-RRIYDLIEL-OH
EBV EBNA 3C
HLA-B27
H-YPLHEQHGM-OH
EBV EBNA 3A
HLA-B35
H-IPSINVHHY-OH
CMV pp65
HLA-B35
H-EENLLDFVRF-OH
EBV
HLA-B44
H-EFFWDANDIY-OH
HCMV
HLA-B44
H-TPRVTGGGAM-OH
HCMV
HLA-B7
For more information and application examples, read our blog posts:
"Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I expression"
"Quality control of peptide pools in personalized cancer therapy"
CMV Sub Peptide Pool (>95% HPLC)
€138.20*
This peptide pool consists of 14 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from cytomegalovirus (CMV).
Only 8 available
CT45A1 Peptide Pool, human
€206.30*
Pool of 45 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through cancer/testis antigen family 45 member A1 (Uniprot ID: Q5HYN5) of Homo sapiens (Human) for T cell assays.
One unit allows the stimulation of 2,5 x 108 cells.
EBV control Peptide Pool (>95% HPLC)
€237.50*
This peptide pool consists of 26 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Epstein-Barr virus (EBV).
One unit allows the stimulation of 2,5 x 108 cells.
Tip
HBV control Peptide Pool (>95% HPLC)
€215.00*
This peptide pool consists of 9 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Hepatitis B virus (HBV).
HCMVA (IE1) Peptide Pool
€301.30*
Peptide pool of 120 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through 55 kDa immediate-early protein 1 (IE-1) (UniProt ID: P13202) of Human cytomegalovirus (HHV-5) frequently used as positive control
One unit allows the stimulation of 2,5 x 108 cells.
HCMVA (IE2) Peptide Pool
€301.30*
Peptide pool of 143 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through 45 kDa immediate-early protein 2 (IE-2) (UniProt ID: P19893) of Human cytomegalovirus (HHV-5) frequently used as positive control
One unit allows the stimulation of 2,5 x 108 cells.
Tip
HCV Sub Peptide Pool (>95% HPLC)
€138.20*
This peptide pool consists of 21 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Hepatitis C virus (HCV).
HIV control Peptide Pool (95% HPLC)
€237.50*
The peptides of this product are supplied as trifluoracetate salts. This pool consists of 22 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from human immunodeficiency virus (HIV).
One unit allows the stimulation of 2,5 x 108 cells.
Tip
Influenza control Peptide Pool (>95% HPLC)
€215.00*
This pool consists of 17 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from influenza.
One unit allows the stimulation of 2,5 x 108 cells.
OVA-Peptid (323-339) (H-2Kb)
€106.60*
OVA-Peptid (323-339) is a linear peptidic epitope (epitope ID 28676) with the amino acid sequence ISQAVHAAHAEINEAGR. The peptide is studied as part of Ovalbumin (UniProt:P01012) from chicken. It is a MHC-II binding epitope, stimulating ovalbumin-specific CD4+ T cells.
OVA-Peptid (323-339) serves as a negative control, when investigating CD4+ T-cell responses.
RSV control Peptide Pool (>95% HPLC)
€215.00*
This pool consists of 28 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from Respiratory Syncytial Virus (RSV).
Tip
Tetanus Toxin Peptide Pool
€475.70*
Peptide pool of 326 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tetanus toxin (UniProt ID: P04958) of Clostridium tetani (strain Massachusetts / E88) for T cell assays (e.g. ELISPOT)
One unit allows the stimulation of 2,5 x 108 cells.
TSGA10 Peptide Pool, human
€380.70*
Control peptide pool of 172 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through human Testis-specific gene 10 protein (UniProt ID Q9BZW7).
One unit allows the stimulation of 2,5 x 108 cells.